NIH supports three companies in jointly developing "artificial pancreas" trials.

We all know that many companies are investing heavily in biotechnology, and Dexcom and Tandem Diabetes Care, which specialize in diabetes, are working with digital health company TypeZero Technologies to develop a closed-loop system for blood sugar control.
the system will include Dexcom's G5 glucose sensor, a tandem insulin pump and a smartphone that will run TypeZero's inControl closed-loop algorithm.
statement, the joint platform will continuously detect blood sugar levels and automatically adjust insulin delivery.
although the main purpose of the system is to regulate the basis or inject insulin, it can also be automatically corrected and allow users to self-replenish the corresponding dose of insulin before meals.
will be tested in an international closed-loop trial of diabetes, funded by the National Institutes of Health (NIH), which will begin later this year.
the experimenters hope to recruit 240 adults with type 1 diabetes to conduct the trial.
Boris Kovatchev, director and lead researcher of the University of Virginia's Diabetes Technology Center, said: "The IDCL trial is a key experiment conducted within a closed-loop control range system, including seven institutions led by the University of Virginia from the United States and three European institutions.
trial, Tandem, Dexcom and TypeZero provided technology integration, representing a new level of development in artificial pancreas research and development.
" Although the closed-loop system enables the "inControl algorithm" to run on current smartphones, the designers hope to integrate Dexcom's G6 sensors into Tandem's t:slim X2 insulin pump and integrate the TypeZero algorithm directly into the insulin pump's touch screen.
partners expect to bring this new design to trial and put into practice in 2017, and they expect the technology, together with the trial data, to be critical to the submission of future regulatory reviews.
currently has an approved "artificial pancreas" on the market, a hybrid closed-loop system from Medtron, which was approved by the FDA in September.
the artificial pancreas is suitable for people with type 1 diabetes aged 14 and older and can be adjusted for background insulin levels by "small input" or "no input" insulin.
system consists mainly of Medtron's MiniMed 670G insulin pump, which regulates insulin delivery of infusion patches and catheters, as well as sensors that continuously monitor sugar levels under the skin.
.